The NMPA published its revised “Good Manufacturing Practice Specification for Medical Device Production” on November 4, 2025, a major update to the original 2014 regulation.
Referenced to ISO 13485, EU MDR, and FDA QMSR/21 CFR 820, the revised GMP reflects China’s effort to integrate international concepts such as total lifecycle control, risk-based quality management, and digital traceability.
For our recorded webinar on NMPA key GMP/QMS updates, please click HERE
For our successful GMP support case, please click HERE
NMPA resumes overseas on-site inspections after Covid-19 pause. Click HERE to learn more
Incorporating three new sections on Quality Assurance, Verification and Validation, and Contract Manufacturing & External Processing, the updated GMP expands from the original structure to 15 chapters with 132 articles.
For overseas manufacturers—even if their devices are produced outside of China—understanding this new framework is essential for successful registration, supply-chain cooperation, and long-term commercial operation within China.
For 2025 regulation of “Production of Imported Medical Devices”, please click HERE
For our comprehensive review on the “Made-in-China” policy, click HERE
Key Features of the 2025 Revision
1. Stronger Lifecycle Risk Management
The Specification calls for a “risk-management mindset” to be embedded across the full product lifecycle—from R&D and design, through production, release, distribution, and post-market activities. Control measures must correspond to the level of risk inherent in the device. For multinational companies partnering with Chinese manufacturers or planning technology transfer, this requirement translates into heightened scrutiny of design files, risk-analysis documentation, and traceability mechanisms.
2. Enhanced Quality Assurance Framework
The updated regulation introduces a structured Quality Assurance System with explicit expectations for:
- design and development compliance
- clarity of management responsibilities
- correctness and suitability of raw materials
- control of intermediates
- robust verification and validation processes
- documented production and testing procedures
- batch/lot release approval
- controlled storage, transportation, and installation
- oversight of contract R&D, outsourced manufacturing, and delegated testing
Foreign manufacturers engaging in OEM/ODM arrangements with Chinese partners should anticipate more formal, contract-based quality obligations and more detailed audits.
3. Clearer Governance of Contract Manufacturing
With China’s medical-device industry rapidly adopting flexible supply-chain models, the Specification clearly delineates responsibilities among registrants, filers, and contracted processors. This transparency offers reassurance to overseas companies seeking partners in China while also raising the compliance bar: every entity in the chain must demonstrate independent quality accountability.
4. Elevating Verification & Validation
A dedicated chapter emphasizes the importance of verification and validation for ensuring reliable, repeatable processes. For foreign companies transferring manufacturing technologies to China, or co-developing products with Chinese entities, this focus means that process validation documentation, equivalency demonstrations, and change-control procedures will face greater scrutiny.
5. Promotion of Digital and Intelligent Manufacturing
China encourages adoption of digitalized and intelligent production, including integration of AI, information technologies, and the Unique Device Identification (UDI) system. Although not prescriptive, the regulation reflects policymakers’ intent to move industry toward a more data-driven, high-transparency model—an alignment with China’s broader modernization initiatives and “Made-in-China” high-quality development strategy. Foreign manufacturers who can demonstrate digital traceability, advanced automation, or data-driven quality control may find smoother cooperation with Chinese regulatory authorities and industrial partners.
Why This Matters for Global Medical-Device Manufacturers
While the Specification is legally binding for production within China, its influence extends across the entire ecosystem of companies selling devices into the market.
1. Registration expectations increasingly reference domestic GMP principles
Even for devices manufactured abroad, NMPA reviewers increasingly expect consistent quality-system logic and documentation—especially in areas of:
- risk management
- lifecycle control
- supplier quality control
- change management
- process validation
Understanding the Specification helps foreign companies anticipate reviewer questions and avoid deficiencies during registration.
2. Chinese partners must comply—and so must the documentation you provide
If an overseas manufacturer uses:
- a Chinese contract manufacturer,
- a Chinese sterilization facility,
- a Chinese packaging operation, or
- local finishing/assembly,
then the entire chain must comply with the new Specification. Global manufacturers need to ensure alignment between their own systems and those of their Chinese partners.
3. China encourages international companies to integrate into local innovation ecosystems
The updated GMP aligns with China’s industrial initiatives promoting high-quality, innovation-driven manufacturing. For multinational companies willing to localize certain processes, build collaborations, or participate in joint R&D, the Specification provides a transparent, structured framework that supports predictable growth.
4. Better alignment with global standards reduces friction and facilitates market entry
By incorporating internationally recognized quality principles, the new Specification narrows the gap between Chinese requirements and global regulatory frameworks. Foreign manufacturers with strong ISO 13485 systems and robust lifecycle documentation will be better positioned for efficient market access.